Revium Rx. (RVRC)

OTCMKTS · Delayed Price · Currency is USD
1.500
0.00 (0.00%)
Jan 20, 2026, 4:00 PM EST
273.97%
Market Cap91.09M
Revenue (ttm)n/a
Net Income (ttm)-2.08M
Shares Out60.73M
EPS (ttm)-0.03
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volumen/a
Average Volume269
Open1.500
Previous Close1.500
Day's Range1.500 - 1.500
52-Week Range0.500 - 1.500
Beta-0.93
RSI47.71
Earnings Daten/a

About Revium Rx.

Revium Rx. operates as a pre-clinical stage biopharmaceutical company focused on the development of nanoparticle-based therapies in the United States. The company develops lipid-based platforms for a variety of uses including antimicrobial resistance and solid tumors. The company specializes in infectious diseases, including antibiotic-resistant infections, solid tumors and vaccination. The company also develops nano-liposomal particles (NLP) based pharmaceutical candidates. It develops nanoparticles-based formulation of a potent antibiotic; no... [Read more]

Sector Healthcare
Founded 1997
Employees 7
Stock Exchange OTCMKTS
Ticker Symbol RVRC
Full Company Profile

Financial Performance

Financial Statements

News

Revium Rx Advances Toward Phase 1 Clinical Development of Nano-Mupirocin to Combat Antibiotic-Resistant Infections

TEL AVIV, Israel, Oct. 21, 2025 (GLOBE NEWSWIRE) -- Revium Rx (formerly Revium Recovery Inc. (OTC: RVRC), a biopharmaceutical company developing advanced lipid-based therapeutics for infectious and on...

3 months ago - GlobeNewsWire

Correction: REVIUM RECOVERY ACQUIRES ANTI-ADDICTION REHABILITATION BUSINESS

OC Beverages changes name to “Revium Recovery, Inc.”, acquires new symbol and implements reverse stock split

5 years ago - GlobeNewsWire